Inherited Cancer Genome Testing - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512243476

Publication Date:

December 6, 2024

Pages:

117

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

The global market for Inherited Cancer Genome Testing was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Inherited Cancer Genome Testing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Inherited Cancer Genome Testing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Inherited Cancer Genome Testing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Inherited Cancer Genome Testing include 23andMe, Agilent Technologies, Bio-Rad Laboratories, Centogene, Color Genomics, Gene By Gene, Illumina, LabCorp and Myriad Genetics, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Inherited Cancer Genome Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Inherited Cancer Genome Testing by region & country, by Type, and by Application.
The Inherited Cancer Genome Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inherited Cancer Genome Testing.
麻豆原创 Segmentation
By Company
23andMe
Agilent Technologies
Bio-Rad Laboratories
Centogene
Color Genomics
Gene By Gene
Illumina
LabCorp
Myriad Genetics
Positive Bioscience
Quest Diagnostics
Thermo Fisher Scientific
Segment by Type:
Breast Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Stomach Cancer
Others
Segment by Application
General Hospitals
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Inherited Cancer Genome Testing manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Inherited Cancer Genome Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Inherited Cancer Genome Testing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Inherited Cancer Genome Testing Product Introduction
1.2 Global Inherited Cancer Genome Testing 麻豆原创 Size Forecast
1.3 Inherited Cancer Genome Testing 麻豆原创 Trends & Drivers
1.3.1 Inherited Cancer Genome Testing Industry Trends
1.3.2 Inherited Cancer Genome Testing 麻豆原创 Drivers & Opportunity
1.3.3 Inherited Cancer Genome Testing 麻豆原创 Challenges
1.3.4 Inherited Cancer Genome Testing 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Inherited Cancer Genome Testing Players Revenue Ranking (2023)
2.2 Global Inherited Cancer Genome Testing Revenue by Company (2019-2024)
2.3 Key Companies Inherited Cancer Genome Testing Manufacturing Base Distribution and Headquarters
2.4 Key Companies Inherited Cancer Genome Testing Product Offered
2.5 Key Companies Time to Begin Mass Production of Inherited Cancer Genome Testing
2.6 Inherited Cancer Genome Testing 麻豆原创 Competitive Analysis
2.6.1 Inherited Cancer Genome Testing 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Inherited Cancer Genome Testing Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inherited Cancer Genome Testing as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Breast Cancer
3.1.2 Lung Cancer
3.1.3 Blood Cancer
3.1.4 Liver Cancer
3.1.5 Stomach Cancer
3.1.6 Others
3.2 Global Inherited Cancer Genome Testing Sales Value by Type
3.2.1 Global Inherited Cancer Genome Testing Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Inherited Cancer Genome Testing Sales Value, by Type (2019-2030)
3.2.3 Global Inherited Cancer Genome Testing Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 General Hospitals
4.1.2 Specialty Clinics
4.2 Global Inherited Cancer Genome Testing Sales Value by Application
4.2.1 Global Inherited Cancer Genome Testing Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Inherited Cancer Genome Testing Sales Value, by Application (2019-2030)
4.2.3 Global Inherited Cancer Genome Testing Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Inherited Cancer Genome Testing Sales Value by Region
5.1.1 Global Inherited Cancer Genome Testing Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Inherited Cancer Genome Testing Sales Value by Region (2019-2024)
5.1.3 Global Inherited Cancer Genome Testing Sales Value by Region (2025-2030)
5.1.4 Global Inherited Cancer Genome Testing Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Inherited Cancer Genome Testing Sales Value, 2019-2030
5.2.2 North America Inherited Cancer Genome Testing Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Inherited Cancer Genome Testing Sales Value, 2019-2030
5.3.2 Europe Inherited Cancer Genome Testing Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Inherited Cancer Genome Testing Sales Value, 2019-2030
5.4.2 Asia Pacific Inherited Cancer Genome Testing Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Inherited Cancer Genome Testing Sales Value, 2019-2030
5.5.2 South America Inherited Cancer Genome Testing Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Inherited Cancer Genome Testing Sales Value, 2019-2030
5.6.2 Middle East & Africa Inherited Cancer Genome Testing Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Inherited Cancer Genome Testing Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Inherited Cancer Genome Testing Sales Value
6.3 United States
6.3.1 United States Inherited Cancer Genome Testing Sales Value, 2019-2030
6.3.2 United States Inherited Cancer Genome Testing Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Inherited Cancer Genome Testing Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Inherited Cancer Genome Testing Sales Value, 2019-2030
6.4.2 Europe Inherited Cancer Genome Testing Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Inherited Cancer Genome Testing Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Inherited Cancer Genome Testing Sales Value, 2019-2030
6.5.2 China Inherited Cancer Genome Testing Sales Value by Type (%), 2023 VS 2030
6.5.3 China Inherited Cancer Genome Testing Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Inherited Cancer Genome Testing Sales Value, 2019-2030
6.6.2 Japan Inherited Cancer Genome Testing Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Inherited Cancer Genome Testing Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Inherited Cancer Genome Testing Sales Value, 2019-2030
6.7.2 South Korea Inherited Cancer Genome Testing Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Inherited Cancer Genome Testing Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Inherited Cancer Genome Testing Sales Value, 2019-2030
6.8.2 Southeast Asia Inherited Cancer Genome Testing Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Inherited Cancer Genome Testing Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Inherited Cancer Genome Testing Sales Value, 2019-2030
6.9.2 India Inherited Cancer Genome Testing Sales Value by Type (%), 2023 VS 2030
6.9.3 India Inherited Cancer Genome Testing Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 23andMe
7.1.1 23andMe Profile
7.1.2 23andMe Main Business
7.1.3 23andMe Inherited Cancer Genome Testing Products, Services and Solutions
7.1.4 23andMe Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.1.5 23andMe Recent Developments
7.2 Agilent Technologies
7.2.1 Agilent Technologies Profile
7.2.2 Agilent Technologies Main Business
7.2.3 Agilent Technologies Inherited Cancer Genome Testing Products, Services and Solutions
7.2.4 Agilent Technologies Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.2.5 Agilent Technologies Recent Developments
7.3 Bio-Rad Laboratories
7.3.1 Bio-Rad Laboratories Profile
7.3.2 Bio-Rad Laboratories Main Business
7.3.3 Bio-Rad Laboratories Inherited Cancer Genome Testing Products, Services and Solutions
7.3.4 Bio-Rad Laboratories Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.3.5 Centogene Recent Developments
7.4 Centogene
7.4.1 Centogene Profile
7.4.2 Centogene Main Business
7.4.3 Centogene Inherited Cancer Genome Testing Products, Services and Solutions
7.4.4 Centogene Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.4.5 Centogene Recent Developments
7.5 Color Genomics
7.5.1 Color Genomics Profile
7.5.2 Color Genomics Main Business
7.5.3 Color Genomics Inherited Cancer Genome Testing Products, Services and Solutions
7.5.4 Color Genomics Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.5.5 Color Genomics Recent Developments
7.6 Gene By Gene
7.6.1 Gene By Gene Profile
7.6.2 Gene By Gene Main Business
7.6.3 Gene By Gene Inherited Cancer Genome Testing Products, Services and Solutions
7.6.4 Gene By Gene Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.6.5 Gene By Gene Recent Developments
7.7 Illumina
7.7.1 Illumina Profile
7.7.2 Illumina Main Business
7.7.3 Illumina Inherited Cancer Genome Testing Products, Services and Solutions
7.7.4 Illumina Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.7.5 Illumina Recent Developments
7.8 LabCorp
7.8.1 LabCorp Profile
7.8.2 LabCorp Main Business
7.8.3 LabCorp Inherited Cancer Genome Testing Products, Services and Solutions
7.8.4 LabCorp Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.8.5 LabCorp Recent Developments
7.9 Myriad Genetics
7.9.1 Myriad Genetics Profile
7.9.2 Myriad Genetics Main Business
7.9.3 Myriad Genetics Inherited Cancer Genome Testing Products, Services and Solutions
7.9.4 Myriad Genetics Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.9.5 Myriad Genetics Recent Developments
7.10 Positive Bioscience
7.10.1 Positive Bioscience Profile
7.10.2 Positive Bioscience Main Business
7.10.3 Positive Bioscience Inherited Cancer Genome Testing Products, Services and Solutions
7.10.4 Positive Bioscience Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.10.5 Positive Bioscience Recent Developments
7.11 Quest Diagnostics
7.11.1 Quest Diagnostics Profile
7.11.2 Quest Diagnostics Main Business
7.11.3 Quest Diagnostics Inherited Cancer Genome Testing Products, Services and Solutions
7.11.4 Quest Diagnostics Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.11.5 Quest Diagnostics Recent Developments
7.12 Thermo Fisher Scientific
7.12.1 Thermo Fisher Scientific Profile
7.12.2 Thermo Fisher Scientific Main Business
7.12.3 Thermo Fisher Scientific Inherited Cancer Genome Testing Products, Services and Solutions
7.12.4 Thermo Fisher Scientific Inherited Cancer Genome Testing Revenue (US$ Million) & (2019-2024)
7.12.5 Thermo Fisher Scientific Recent Developments
8 Industry Chain Analysis
8.1 Inherited Cancer Genome Testing Industrial Chain
8.2 Inherited Cancer Genome Testing Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Inherited Cancer Genome Testing Sales Model
8.5.2 Sales Channel
8.5.3 Inherited Cancer Genome Testing Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

23andMe
Agilent Technologies
Bio-Rad Laboratories
Centogene
Color Genomics
Gene By Gene
Illumina
LabCorp
Myriad Genetics
Positive Bioscience
Quest Diagnostics
Thermo Fisher Scientific

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.